ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion MarketFREMONT, CA - January 15, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (
NASDAQABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, is proud to announce the advancements in its innovative treatments for Major Depressive Disorder (MDD) and Attention-Deficit/Hyperactivity Disorder (ADHD), highlighting the promising results achieved through rigorous clinical research and development.
AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing FeesLicensing Fees From AiBtl and Strategic Partners Now Total $696,000, Bolstering Confidence in AiBtl’s Plans
AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing FeesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price RequirementSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price RequirementFREMONT, CA - January 13, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (
NASDAQABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, is pleased to announce that Nasdaq has granted the Company an additional 180-day grace period, until July 7, 2025, to regain compliance with the Nasdaq Capital Market’s minimum $1.0 bid price per share requirement.
ABVC BioPharma and ForSeeCon: An Update on Alliance's Ophthalmology-Related ProductsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic AchievementsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AISearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing DealsFREMONT, CA - (NewMediaWire) - July 02, 2024 - ABVC BioPharma, Inc. (
NASDAQABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and its subsidiary BioFirst Corporation received a milestone payment of 10M shares of ForSeeCon Eye Corporation’s securities to which the parties impute a value of $6 per share based on an internal valuation1 and a cash payment of $196,000 for its global licensing agreement with ForSeeCon Eye Corporation, which is for the Company's Ophthalmology pipeline, including the medical device Vitargus® (valued at $187M, by third-party valuer) (the "Licensed Products"). ForSeeCon Eye Corporation is a private company registered in the British Virgin Islands. With this payment, the Company has now received aggregate cash payments of $296,000 from ForSeeCon and Oncox ($100,000), one of the Company’s other licensees. In addition to the cash payment, the Company has already received stocks from AiBtl (another licensee) and ForSeeCon, which the company believes are valued at $460M and $60M, respectively.2 The Company expects to receive additional stocks from OncoX that the Company believes is valued at $50M,3 up to $23.7M in cash and royalties of up to $370M from net sales from all three licensees (AiBtl, ForSeeCon, and OncoX), although such net sales cannot be guaranteed.
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing DealsFREMONT, CA - (NewMediaWire) - July 02, 2024 - ABVC BioPharma, Inc. (
NASDAQABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and its subsidiary BioFirst Corporation received a milestone payment of 10M shares of ForSeeCon Eye Corporation’s securities to which the parties impute a value of $6 per share based on an internal valuation1 and a cash payment of $196,000 for its global licensing agreement with ForSeeCon Eye Corporation, which is for the Company's Ophthalmology pipeline, including the medical device Vitargus® (valued at $187M, by third-party valuer) (the "Licensed Products"). ForSeeCon Eye Corporation is a private company registered in the British Virgin Islands. With this payment, the Company has now received aggregate cash payments of $296,000 from ForSeeCon and Oncox ($100,000), one of the Company’s other licensees. In addition to the cash payment, the Company has already received stocks from AiBtl (another licensee) and ForSeeCon, which the company believes are valued at $460M and $60M, respectively.2 The Company expects to receive additional stocks from OncoX that the Company believes is valued at $50M,3 up to $23.7M in cash and royalties of up to $370M from net sales from all three licensees (AiBtl, ForSeeCon, and OncoX), although such net sales cannot be guaranteed.
ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion MarketSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in RevenueFREMONT, CA - (NewMediaWire) - June 12, 2024 - ABVC BioPharma, Inc. (
NASDAQABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company received the first $100,000 cash payment towards the total possible $5M cash license fee under the various licensing agreements it maintains with OncoX BioPharma, Inc. ("OncoX").
ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24MSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50MFREMONT, CA - (NewMediaWire) - May 09, 2024 - ABVC BioPharma, Inc. (
NASDAQABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that in its fight against pancreatic cancer, the Company, together with its affiliate Rgene Corporation, entered into a definitive agreement with OncoX BioPharma, Inc., a private company registered in the British Virgin Islands, to collaborate on combination therapy it believes will help treat Pancreatic Cancer and improve patient outcomes significantly. ABVC and its affiliate are set to receive an aggregate license fee of $12,500,000 in the form of cash or shares of OncoX securities within 30 days of executing the agreement, with an additional milestone payment of $1,250,000 in cash after OncoX's next round of fundraising, of which there can be no guarantee. ABVC and its affiliate are also entitled to receive payments in cash of at least $100,000 towards the licensing fees and deductible from the second milestone payment, as well as royalties of 5% of net sales, up to $12,500,000, after the launch of the licensed product, which remains uncertain.
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareFREMONT, CA - (NewMediaWire) - April 18, 2024 - ABVC BioPharma, Inc. (
NASDAQABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company's subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision medicine industry. The acquisition includes Malaysian Import Trading Company, Direct Sales Company, and Taiwanese Direct Sales Company, which are estimated to be approximately equivalent to $8.33M. AiBtl purchased 100% shares of TT Life by swapping its 1.66M shares at $5 per share. This strategic move positions AiBtl to expand its portfolio further and accelerate innovation in the rapidly growing precision medicine market while consolidating the financials, including the revenue, profit, and cash flow, with TT Life.
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per ShareSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
